Ardelyx, Inc. (FRA:41X)

Market Cap	1.57B +27.7%
Revenue (ttm)	339.41M +58.1%
Net Income	-48.20M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	80.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	284
Open	6.50
Previous Close	6.62
Day's Range	6.50 - 6.50
52-Week Range	2.89 - 6.75
Beta	n/a
RSI	60.90
Earnings Date	Feb 27, 2026

About Ardelyx

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 395
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41X

Financial Performance

In 2024, Ardelyx's revenue was $333.62 million, an increase of 168.06% compared to the previous year's $124.46 million. Losses were -$39.14 million, -40.76% less than in 2023.

Financial numbers in USD